1. Home
  2. WES vs UTHR Comparison

WES vs UTHR Comparison

Compare WES & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WES
  • UTHR
  • Stock Information
  • Founded
  • WES 2007
  • UTHR 1996
  • Country
  • WES United States
  • UTHR United States
  • Employees
  • WES N/A
  • UTHR N/A
  • Industry
  • WES Natural Gas Distribution
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • WES Utilities
  • UTHR Health Care
  • Exchange
  • WES Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • WES 15.0B
  • UTHR 20.7B
  • IPO Year
  • WES 2008
  • UTHR 1999
  • Fundamental
  • Price
  • WES $38.68
  • UTHR $466.53
  • Analyst Decision
  • WES Hold
  • UTHR Buy
  • Analyst Count
  • WES 6
  • UTHR 12
  • Target Price
  • WES $40.00
  • UTHR $495.08
  • AVG Volume (30 Days)
  • WES 1.7M
  • UTHR 573.8K
  • Earning Date
  • WES 11-04-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • WES 9.43%
  • UTHR N/A
  • EPS Growth
  • WES N/A
  • UTHR 16.08
  • EPS
  • WES 3.38
  • UTHR 26.38
  • Revenue
  • WES $3,740,425,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • WES $7.07
  • UTHR $13.68
  • Revenue Next Year
  • WES $7.20
  • UTHR $5.63
  • P/E Ratio
  • WES $11.42
  • UTHR $17.53
  • Revenue Growth
  • WES 5.81
  • UTHR 13.50
  • 52 Week Low
  • WES $33.60
  • UTHR $266.98
  • 52 Week High
  • WES $43.33
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • WES 51.33
  • UTHR 65.95
  • Support Level
  • WES $37.75
  • UTHR $444.04
  • Resistance Level
  • WES $39.74
  • UTHR $464.27
  • Average True Range (ATR)
  • WES 0.77
  • UTHR 15.76
  • MACD
  • WES 0.11
  • UTHR 1.56
  • Stochastic Oscillator
  • WES 60.39
  • UTHR 79.80

About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests

Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: